Sandy L. Noonan

ACCOUNTING MANAGER

snoonan@archltd.com

Sandy L. NoonanIn her role as Accounting Manager, Sandy Noonan manages the accounting and finance functions at ARCH. Her responsibilities include forecasting, billing, payables and receivables, and coordination of project accounting and Construction In Progress tracking.

Ms. Noonan’s background includes 15 years of extensive experience in financial analysis roles in pharmaceutical and consumer markets. At Searle Pharmaceuticals, her experience included leading a financial analysis group as Associate Director of Portfolio and Decision Analysis. In this role Sandy participated on cross functional teams to provide strategic and financial analysis to support R&D portfolio optimization, and was a liaison with Pfizer to ensure financial projections and key initiatives of co-marketed/co-developed product platform were consistent between the partner companies. In addition, she held the role of Associate Director of Business and Development Analysis, where she was responsible for detailed financial analysis of business opportunities, including mergers and acquisitions, in-licensing and out-licensing opportunities, joint ventures, and other business opportunities. Ms. Noonan has also worked in Technical Operations finance, managing the accounting and finance functions of the chemical manufacturing operations.

Prior to her pharmaceutical experience, Ms. Noonan worked in operational and cost accounting positions at consumer goods companies, including Alberto Culver and Swift Eckrich, where she led the cost accounting process and worked with manufacturing operations personnel to identify manufacturing finance process improvements, providing detailed analyses of manufacturing variances to management.

Education

Ms. Noonan received her Bachelor of Science in Accounting from the University of South Florida and her Master of Business Administration degree with concentration in Finance from DePaul University. She has also received training and is certified in Decision Analysis from the Strategic Decisions Group.